Avistone Pharmaceuticals Biotechnology key facts
as of Oct 2026- Developer of innovative drugs for tumor treatment.
- Avistone Pharmaceuticals Biotechnology is valued at approximately $628.3M as of Oct 2026 (last reported valuation).
- It has raised $372.0M; the latest was IPO in Sep 2025.
- Notable investors include IDG Capital, Bain Capital, Cathay Capital, CMG SDIC Fund, Vivo Capital — 11 tracked in total.
- Status: In IPO Registration.
Avistone Pharmaceuticals Biotechnology's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Avistone Pharmaceuticals Biotechnology: the Monday email on marks, rounds and moves
Avistone Pharmaceuticals Biotechnology funding rounds
No funding rounds for Avistone Pharmaceuticals Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Avistone Pharmaceuticals Biotechnology
11+Avistone Pharmaceuticals Biotechnology valuation
Avistone Pharmaceuticals Biotechnology's last reported valuation was $628 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Avistone Pharmaceuticals Biotechnology investors
11 investors are on record for Avistone Pharmaceuticals Biotechnology, including IDG Capital, Bain Capital, Cathay Capital and CMG SDIC Fund. By type, the record holds 4 venture capital firms, 2 private equity firms and 1 growth equity firm.
About Avistone Pharmaceuticals Biotechnology
Developer of innovative drugs for tumor treatment. The company develops targeted cancer therapies, committing to treat cancer through precision medicine.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Employees
- 356
- Website
- avistonebio.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.